For the first time in Australia, a weight loss drug has been approved to also treat cardiovascular disease in overweight and obese patients. The ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

A recent study from the University of Pennsylvania has confirmed that the injectable medication semaglutide can lead to major ...

For the first time a semaglutide weight loss drug has been approved for use in Australia to also treat cardiovascular disease ...

Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From ...

HFpEF outcomes were improved with semaglutide, compared with placebo, among patients with obesity-related HFpEF and type 2 diabetes.

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

A new study increases max-dose guidance for semaglutide. This offers hope for those who didn’t reach their weight goals. The ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

New York, New York-- (Newsfile Corp. - February 9, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...